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Objective. To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the 
European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
Methods. This international initiative had four phases. 1) Evaluation of antinuclear antibody (ANA) as an entry cri-
terion through systematic review and meta- regression of the literature and criteria generation through an international 
Delphi exercise, an early patient cohort, and a patient survey. 2) Criteria reduction by Delphi and nominal group tech-
nique exercises. 3) Criteria definition and weighting based on criterion performance and on results of a multi- criteria 
decision analysis. 4) Refinement of weights and threshold scores in a new derivation cohort of 1,001 subjects and 
validation compared with previous criteria in a new validation cohort of 1,270 subjects.
Results. The 2019 EULAR/ACR classification criteria for SLE include positive ANA at least once as obligatory en-
try criterion; followed by additive weighted criteria grouped in 7 clinical (constitutional, hematologic, neuropsychiatric, 
mucocutaneous, serosal, musculoskeletal, renal) and 3 immunologic (antiphospholipid antibodies, complement pro-
teins, SLE- specific antibodies) domains, and weighted from 2 to 10. Patients accumulating ≥10 points are classified. 
In the validation cohort, the new criteria had a sensitivity of 96.1% and specificity of 93.4%, compared with 82.8% 
sensitivity and 93.4% specificity of the ACR 1997 and 96.7% sensitivity and 83.7% specificity of the Systemic Lupus 
International Collaborating Clinics 2012 criteria.
This criteria set has been approved by the European League Against Rheumatism (EULAR) Executive Com-
mittee and the American College of Rheumatology (ACR) Board of Directors. This signifies that the criteria 
set has been quantitatively validated using patient data, and it has undergone validation based on an 
independent data set. All EULAR/ACR-approved criteria sets are expected to undergo intermittent updates.
The ACR is an independent, professional, medical and scientific society that does not guarantee, warrant, or 
endorse any  commercial product or service.
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Conclusion. These new classification criteria were developed using rigorous methodology with multidisciplinary 
and international input, and have excellent sensitivity and specificity. Use of ANA entry criterion, hierarchically clus-
tered, and weighted criteria reflects current thinking about SLE and provides an improved foundation for SLE research.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a complex autoim-
mune disease with variable clinical features (1,2). SLE manifesta-
tions are associated with multiple autoantibodies, ensuing immune 
complex formation and deposition, and other immune processes 
(2,3). This complex clinical presentation and pathogenesis makes 
SLE a difficult disease to grasp and define. Classification crite-
ria are essential for the identification of relatively homogeneous 
groups of patients for inclusion in research studies and trials (4,5). 
The 1982 revised American College of Rheumatology (ACR) SLE 
classification criteria (6) and their 1997 revision (7) have been used 
worldwide. Since then, our understanding of the disease has 
advanced. Additional specific skin manifestations were described, 
some clinical symptoms were better understood, and immuno-
logic tests, such as diminished levels of serum complement com-
ponents C3 and C4 or testing for anti–β2- glycoprotein I antibodies, 
entered routine clinical practice. Better understanding of organ 
system involvement, such as mucocutaneous abnormalities, led 
to questions about whether some of the independently counted 
criteria were in fact manifestations of the same phenomenon (8).
The 2012 Systemic Lupus International Collaborating Clin-
ics (SLICC) classification criteria addressed many of these issues 
(9). Mucocutaneous and neuropsychiatric manifestations were 
added, as were hypocomplementemia and new antiphospholipid 
antibody tests; and criteria definitions were refined. The SLICC 
criteria emphasized that SLE is primarily an autoantibody  disease, 
requiring at least one immunologic criterion to be present, and 
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categorized histology- proven nephritis compatible with SLE as 
sufficient for classification, if antinuclear antibodies (ANAs) or anti-
bodies to double- stranded DNA (dsDNA) were present. While 
achieving their goal of increasing sensitivity, the SLICC criteria 
have lower specificity than the 1997 ACR criteria (9,10).
Existing SLE classification criteria perform better in patients 
with longstanding disease than in new- onset SLE (11), and there 
is an increasing recognition and demand that subjects with early 
SLE should be included in clinical studies and trials. We there-
fore attempted to enrich our sample populations for early SLE in 
 several phases of the project.
In parallel with improved understanding of SLE, the field 
of classification criteria development has also seen advances 
(4,12–14). In order to minimize investigator bias, it is now recom-
mended that the cohorts in which the criteria are tested are from 
independent centers (4). Other methodologic recommendations 
include a balanced use of both expert- based and data- driven meth-
ods, and inclusion of the patient perspective (13,14). The approach 
chosen for these 2019 European League Against Rheumatism 
(EULAR)/ACR SLE classification criteria was specifically designed 
to maintain this balance and to uphold rigorous methodology.
METHODS
Methodologic overview. Using a methodologic approach 
based on measurement science the criteria were developed in 
four phases (10): 1) criteria generation, 2) criteria reduction, 3) 
criteria definition and weighting, and 4) refinement and validation 
(Figure  1). The whole initiative was overseen by a 12- member 
steering committee (MA, KHC, DID, MM, RR- G, JSS, DW, DTB, 
DLK, DJ, TD, and SRJ) nominated by EULAR and the ACR in 
equal numbers, based on SLE and/or methodologic experience 
and previous involvement in international projects.
The current project, jointly supported by the EULAR and the 
ACR, was originally based on two key concepts. One, we hypoth-
esized that the presence of ANA would be better employed as 
an entry criterion than as a classification criterion (10). Such an 
approach was thought to reflect underlying SLE pathogenesis, and 
take into account ANA test characteristics of high sensitivity and 
limited specificity. Two, we expected individual criteria would not be 
of equal utility (weight) for the classification of SLE (15), for exam-
ple, mucosal ulcers versus biopsy- proven lupus nephritis. Accord-
ingly, the validity of using positive ANA as an entry criterion was 
explicitly addressed in phase I of the current activity (16). Likewise, 
methodologic strategies to develop weighted criteria were used.
Phase I: Criteria generation. The purpose of phase I 
was to test ANA as a potential entry criterion and identify can-
didate criteria that should be considered for SLE classification 
using both data- based and expert- based methods, including 
the patient perspective. Phase Ia comprised a systematic liter-
ature review of Medline, Embase, and the Cochrane databases 
with meta- regression to evaluate the operating characteristics of 
ANA testing for consideration as an entry criterion (16). Phase Ib 
 consisted of a Delphi exercise of international SLE experts from 
the Americas, Europe, and Asia (17). These experts included 
Figure 1. Development and validation of systemic lupus erythematosus (SLE) classification criteria. ANA = antinuclear antibody.
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rheumatologists, dermatologists, nephrologists, pediatricians, 
and non- clinical SLE researchers, providing a broad perspective. 
The Delphi participants were asked to nominate a broad set of 
items potentially useful in the classification of SLE (17). In rounds 
2 and 3, participants rated the items from 1 (not at all appro-
priate) to 9 (completely appropriate) for classification of SLE. 
Criteria were retained if they reached a median rating of ≥6.5; 
that is, at least 50% of the ratings in the high range (7, 8, or 9). 
Participants were also asked about the importance of ANA and 
histopathology for classification of SLE. Phase Ic established 
an international cohort of patients with early SLE or conditions 
mimicking SLE to identify criteria that may discriminate subjects 
with early (less than 12 months) disease (18). Phase Id com-
prised a cross- sectional survey of SLE patients, administered 
via the quarterly journal of the German SLE patient organiza-
tion, which asked about symptoms within 1 year before and after 
the patient’s diagnosis of SLE (19). While at a risk of recall bias 
and not necessarily representative of other regions worldwide, 
this survey was done to explicitly take a patient standpoint into 
account.
For phases II and III, additional renowned European and 
North American SLE experts were nominated by the steering 
committee and invited to participate.
Phase II: Criteria reduction. Phase IIa. The objective 
of this phase was to select a set of criteria from phase I that 
maximized the likelihood of accurate classification of SLE, par-
ticularly of early disease. An independent panel of seven of the 
international SLE experts (RC, NC- C, DDG, BHH, FH, EM, and 
JS- G) ranked the candidate criteria from phase I. A consensus 
meeting of 19 international SLE experts (n = 7 nominal group 
technique [NGT] experts + steering committee + DK [modera-
tor]) using NGT was conducted to reduce the list of criteria (20). 
Data for each candidate criterion were reviewed and discussed 
until consensus was achieved. The NGT experts voted on items 
to be retained.
Phase IIb. NGT participants pointed out that some criteria 
could be correlated. With the idea of potentially clustering criter-
ia into domains, associations between candidate criteria were 
evaluated separately in two cohorts, the phase Ic early SLE and 
the Euro- lupus cohorts (21).
Phase III: Criteria definition and weighting. Phase 
IIIa. The operating characteristics of the retained candidate cri-
teria were evaluated by literature review. Candidate criteria were 
hierarchically organized into clinical and immunologic domains, 
and definitions for the candidate criteria were iteratively refined. 
SLE patient advocates participated in the review of data and the 
steering committee discussions (22).
Phase IIIb. One hundred sixty- four case vignettes reflect-
ing broad SLE clinical presentation were sampled from SLE 
centers across several countries. A panel of six of the inter-
national experts not involved in earlier phases of the project 
(BD, SJ, WJM, GR- I, MS, and MBU) and 11 members of the 
steering committee assessed and ranked a representative 
sample of the cases. Subsequently, at a face- to- face meeting, 
this panel of 17 international SLE experts iteratively compared 
pairs of criteria, using multicriteria decision analysis facilitated 
by 1000Minds software (23). The panel unanimously agreed 
to further reduce the list of criteria. Based on the results, 
provisional criteria weights were assigned and a provisional 
threshold score for classification was determined as the low-
est score at which the expert panel had achieved consensus 
on classifying a case vignette as SLE (24).
Phase IV: Refinement and validation. International 
SLE experts not involved in phase II or phase III panels were 
asked to contribute cases diagnosed as SLE and controls with 
conditions mimicking SLE sampled from patients evaluated at 
their centers. Each center was asked to contribute up to 100 
cases and an equal number of controls, preferentially sampling 
those with early disease, and regardless of their specific clin-
ical or immunologic manifestations. Pseudonymized data on 
the criteria were collected using a standardized data collection 
form. Ethics committee approval and informed consent were 
obtained as per local requirements. The status (“SLE” or not) 
of each case underwent independent adjudication by three of 
four SLE experts (GB, BFH, NL, and CT) from different centers. 
Queries were sent back to the submitting investigator for clari-
fication. Of this cohort, 501 SLE and 500 control subjects were 
randomly selected to comprise the derivation cohort, while the 
remaining 696 SLE and 574 control subjects formed the valida-
tion cohort.
Refinement. The performance of the draft criteria set was 
iteratively tested in the derivation cohort. A data- driven thresh-
old for classification was determined by receiver operating char-
acteristics (ROC) analysis and compared with the provisional 
expert- based consensus threshold. The data of SLE subjects 
below the threshold (misclassified) were reviewed for groups of 
patients with unequivocal SLE who still missed classification, and 
criteria weights adjusted slightly, while preserving the weighting 
hierarchy (details below in Results, Phase IV section). Sensitivity 
and specificity were tested against the ACR 1997 and the SLICC 
2012 criteria. In addition, ANA as an entry criterion was tested 
against not having an entry criterion. Finally, the criteria weights 
were simplified to whole numbers. Refinements to the criteria set 
were presented to the steering committee and phase III expert 
panel, and unanimously endorsed.
Validation. The sensitivity and specificity of the final criteria 
were tested in the validation cohort and compared with previous 
SLE criteria sets.
Statistical analysis. Descriptive statistics were used to sum-
marize the data. Confidence intervals (CIs) were calculated us-
ing the bias- corrected and accelerated bootstrap method (BCa 
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method) with B = 2000 bootstrap samples. The BCa method 
resamples the input data B times (with replacement) and calcu-
lates the required statistics (sensitivity, specificity, AUC). Based 
on the B bootstraps samples, the bias- correction is applied and 
the associated 95% CIs for the statistics are estimated. The BCa 
method has proven to yield very accurate coverage of estimated 
CIs (25). The number B of bootstrap resamples is recommended 
to be at least B = 1,000. We have chosen B = 2,000 and addi-
tionally checked if B = 5,000 bootstraps changed the estimated 
confidence bounds, which was not the case. Statistical analyses 
were performed using R, v.3.4.0 (The R Foundation of Statistical 
Computing).
RESULTS
Phase I: Criteria generation. Phase Ia: ANA as an 
 entry criterion. A systematic review of Medline, Embase, 
and the Cochrane database identified 13,080 patients from 
64 studies reporting ANA by immunofluorescence on HEp- 2 
cells. Meta- regression of the operating characteristics of ANA 
found a sensitivity of 97.8% (95% CI 96.8–98.5%) for ANA of 
≥1:80, supporting use of ANA as an entry criterion (16). Since 
some SLE centers do not have access to HEp- 2 ANA, and in 
view of ongoing work on the standardization of serology and 
potential future advances in the field, the steering committee 
and additional autoantibody consultants (MJF and PLM) rec-
ommended the provision “or an equivalent positive ANA test. 
Testing by immunofluorescence on HEp- 2 cells or a solid- 
phase ANA screening immunoassay with at least equivalent 
performance is highly recommended.”
Phase Ib: Delphi exercise. One hundred forty- seven inter-
national SLE experts nominated 145 candidate criteria (17). By 
rating the appropriateness for SLE classification, the participants 
in the second and third Delphi rounds reduced the list to 40 can-
didate criteria (Supplementary Table 1, on the Arthritis & Rheu-
matology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40930/ abstract).
Phase Ic: International early SLE cohort. The cohort com-
prised 616 subjects who had been referred for possible SLE 
with a disease duration of less than 1 year (n = 389 early SLE 
and n = 227 mimicking diseases) from North America, Europe, 
Asia, and South America (18). In addition to supporting many of 
the 40 candidate criteria derived from the Delphi exercise, the 
comparison between early SLE and non- SLE patients showed 
that fever occurred more frequently (34.5% versus 13.7%; 
P < 0.001) in SLE, while SLE patients less commonly suffered 
from arthralgias (20.3% versus 42.7%; P = 0.001) and fatigue 
(28.3% versus 37%; P = 0.02).
Phase Id: Patient survey. Three hundred thirty- nine 
SLE patients (>99% Caucasian, 93% female) responded to 
the survey (19). More than half of these patients  reported 
 mucocutaneous findings in the first year of their disease (Sup-
plementary Table 1, http://onlin elibr ary.wiley.com/doi/10.1002/ 
art.40930/ abstract), but also fatigue (89%), joint pain (87%), 
and fever (54%) (19). Given that these items were highlight-
ed both in the early SLE cohort and the patient survey, fe-
ver, fatigue, and arthralgias were forwarded to the next phase 
in addition to the 40 Delphi items. Accordingly, phases Ia–Id 
resulted in a total of 43 candidate criteria for consideration 
(Supplementary Table 1).
Phase II: Criteria reduction. Phase IIa. The expert panel 
NGT exercise reduced the candidate criteria from 43 to 21 (26). 
The panel distinguished potential “entry criteria,” which would be 
required for classification, from potential “additive criteria.” They 
endorsed “positive ANA (≥1:80 by HEp- 2 immunofluorescence)” 
as an entry criterion. The 20 remaining additive criteria includ-
ed: lupus nephritis by renal biopsy, autoantibodies, cytopenias, 
fever, arthritis, serositis, mucocutaneous and neuropsychiatric 
manifestations (Supplementary Table 1).
Phase IIb. Associations between the candidate criteria were 
evaluated in 389 subjects in the early SLE cohort and the 1,000 SLE 
subjects of the Euro- lupus cohort. Modest statistically significant 
correlations were limited to the mucocutaneous  (r = 0.22–0.30), 
neurologic (r = 0.22), and immunologic (r = 0.33) domains in the 
early SLE cohort, and this modest correlation was replicated in the 
Euro- lupus cohort (21). Given these associations, criteria were clus-
tered within domains, so that only 1 criterion within each domain 
would be counted.
Phase III: Criteria definition and weighting. Phase 
IIIa. Based on the literature, definitions of the 20 candidate 
additive criteria were refined, using a data- driven evaluation of 
operating characteristics (22), retaining only feasible items with 
a prevalence of at least 1% according to literature. Literature 
review led to the consensus decision to evaluate 5 different 
candidate criteria within the neuropsychiatric domain (deliri-
um, psychosis, seizure, mononeuropathy, cranial neuropathy) 
and potential separation of acute pericarditis from pleural or 
pericardial effusions and between diminished C3 or C4 ver-
sus diminished C3 and C4. The resulting 23 candidate criteria 
(Supplementary Table 1, on the Arthritis & Rheumatology web 
site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40930/ 
abstract) were organized into 7 clinical and 3 immunologic 
domains, with hierarchical clustering (22). Only the highest- 
ranking item in each domain was to be counted. Instead of 
devising exclusion definitions for each criterion, the decision 
was made to attribute any item to SLE only if no more likely ex-
planation was present. For leukopenia and joint involvement, it 
was decided to formally test alternative definitions in the der-
ivation cohort. Given the importance of testing for antibodies, 
particularly for anti- dsDNA, for which tests of relatively low 
specificity are in use, great care was taken to precisely define 
testing (Table 1).
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Table 1. Definitions of SLE classification criteria*
Criteria Definition
Antinuclear antibodies (ANA) ANA at a titer of ≥1:80 on HEp- 2 cells or an equivalent positive test at least once. Testing by 
immunofluorescence on HEp- 2 cells or a solid- phase ANA screening immunoassay with 
at least equivalent performance is highly recommended
Fever Temperature >38.3°C
Leukopenia White blood cell count <4,000/mm³
Thrombocytopenia Platelet count <100,000/mm³
Autoimmune hemolysis Evidence of hemolysis, such as reticulocytosis, low haptoglobin, elevated indirect bilirubin, 
elevated LDH, AND positive Coombs’ (direct antiglobulin) test
Delirium Characterized by 1) change in consciousness or level of arousal with reduced ability to 
focus, 2) symptom development over hours to <2 days, 3) symptom fluctuation through-
out the day, 4) either 4a) acute/subacute change in cognition (e.g., memory deficit or 
disorientation), or 4b) change in behavior, mood, or affect (e.g., restlessness, reversal of 
sleep/wake cycle)
Psychosis Characterized by 1) delusions and/or hallucinations without insight and 2) absence of 
delirium
Seizure Primary generalized seizure or partial/focal seizure
Non- scarring alopecia Non- scarring alopecia observed by a clinician†
Oral ulcers Oral ulcers observed by a clinician†
Subacute cutaneous OR discoid 
lupus
Subacute cutaneous lupus erythematosus observed by a clinician:†
Annular or papulosquamous (psoriasiform) cutaneous eruption, usually  
photodistributed
 If skin biopsy is performed, typical changes must be present (interface vacuolar derma-
titis consisting of a perivascular lymphohistiocytic infiltrate, often with dermal mucin 
noted).
OR
Discoid lupus erythematosus observed by a clinician:†
Erythematous-violaceous cutaneous lesions with secondary changes of atrophic scarring, 
dyspigmentation, often follicular hyperkeratosis/plugging (scalp), leading to scarring 
alopecia on the scalp
If skin biopsy is performed, typical changes must be present (interface vacuolar dermatitis 
consisting of a perivascular and/or periappendageal lymphohistiocytic infiltrate. In the 
scalp, follicular keratin plugs may be seen. In longstanding lesions, mucin deposition may 
be noted)
Acute cutaneous lupus Malar rash or generalized maculopapular rash observed by a clinician†
If skin biopsy is performed, typical changes must be present  
(interface vacuolar dermatitis consisting of a perivascular lymphohistiocytic infiltrate, 
often with dermal mucin noted. Perivascular neutrophilic infiltrate may be present early 
in the course)
Pleural or pericardial effusion Imaging evidence (such as ultrasound, x- ray, CT scan, MRI) of pleural or pericardial 
effusion, or both
Acute pericarditis ≥2 of 1) pericardial chest pain (typically sharp, worse with inspiration, improved by leaning 
forward), 2) pericardial rub, 3) EKG with new widespread ST elevation or PR depression, 4) 
new or worsened pericardial effusion on imaging (such as ultrasound, x- ray, CT scan, MRI)
Joint involvement EITHER 1) synovitis involving 2 or more joints characterized by swelling or effusion OR 2) 
tenderness in 2 or more joints and at least 30 minutes of morning stiffness
Proteinuria >0.5 g/24 hours Proteinuria >0.5 g/24 hours by 24- hour urine or equivalent spot urine protein- to- 
creatinine ratio
Class II or V lupus nephritis on renal 
biopsy according to ISN/RPS 2003 
classification
Class II:
Mesangial proliferative lupus nephritis: purely mesangial hypercellularity of any degree or 
mesangial matrix expansion by light microscopy, with mesangial immune deposit. A few 
isolated subepithelial or subendothelial deposits may be visible by immunofluorescence 
or electron microscopy, but not by light microscopy
Class V:
Membranous lupus nephritis: global or segmental subepithelial immune deposits or their 
morphologic sequelae by light microscopy and by immunofluorescence or electron 
microscopy, with or without mesangial alterations
(Continued)
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Phase IIIb. The 1.5- day in- person consensus meeting us-
ing multicriteria decision analysis involved 74 decisions between 
pairs of criteria. Criteria weights were calculated by 1000Minds 
software based on these decisions (Table 2). International Socie-
ty of Nephrology/Renal Pathology Society class III or IV nephritis 
consistently attained higher weight than class II or V nephritis, 
so lupus nephritis by histology was separated into 2 different 
criteria. Class VI lupus nephritis as an end- stage manifestation 
was unanimously eliminated. Likewise, the experts unanimous-
ly voted to not retain mononeuropathy and cranial neuropathy, 
which had been included into the set of potential neuropsychiat-
ric items in phase IIIa but turned out to add little to SLE classifi-
cation. The use of weighted criteria led to a sum score that is a 
measure of the relative probability of a subject having SLE, with 
higher scores indicating higher likelihood. Experts reached full 
consensus on a classification of SLE at a provisional threshold 
score of >83 of a theoretical maximum of 305 (24).
Phase IV: Refinement and validation. Twenty- 
one centers from the US, Canada, Mexico, Austria, Croatia, 
France, Germany, Greece, Hungary, Italy, Portugal, Spain, the 
UK, Turkey, Hong Kong, and Japan submitted a total of 2,339 
cases from their cohorts; 1,197 SLE and 1,074 non- SLE diag-
noses (Table 3) were verified by 3 adjudicators blinded to the 
proposed classification criteria system. Due to lack of con-
sensus during adjudication, 68 subjects (2.9%) were excluded 
from the analysis.
Derivation cohort. Of the 2,271 triple- adjudicated cases, 
501 SLE and 500 non- SLE cases were randomly assigned to 
the derivation cohort. The provisional weighting system derived 
from phase III was tested in the derivation cohort. ROC analysis 
suggested a data- driven threshold of ≥70 (of a maximum of 305), 
with a sensitivity of 95.4% and a specificity of 95.2%, which was 
superior to the consensus- derived provisional threshold of >83 
that had high specificity (98.8%), but lower sensitivity (81.6%). 
Review of subjects below the threshold of 70 identified a sub-
group of SLE subjects with joint involvement and/or leukopenia. 
Thus, weights for leukopenia and joint involvement were each 
adjusted (Table 2) to reduce misclassification. When alternative 
definitions for leukopenia and joint involvement were tested, leu-
kopenia defined as a white blood cell count (WBC) <4000/mm3 
at least once (9) also had a slightly higher sensitivity + specificity 
(1.944 versus 1.942) than leukopenia defined as WBC <4,000/
mm3 on 2 or more occasions (6,26). Joint involvement defined 
as EITHER “synovitis involving 2 or more joints, characterized 
by swelling or effusion,” OR “tenderness in 2 or more joints and 
at least 30 minutes of morning stiffness” (9) had a higher com-
bined sensitivity and specificity than arthritis defined simply as 
synovitis of 2 or more joints (1.944 versus 1.900). When retest-
ed, the revised criteria had increased sensitivity, and maintained 
sensitivity + specificity. Evaluating ANA as an entry criterion, the 
criteria with the ANA entry criterion had better performance than 
without (sensitivity + specificity 1.944 versus 1.930). Next, the 
weights were simplified by division to whole numbers to achieve 
a threshold of 10 (Table 2). In the derivation cohort, the sensitivity 
and specificity of the final criteria set (Figure 2) were reaching the 
performance benchmarks set for this project (Table 4).
Validation. The validation cohort, that is, the full cohort mi-
nus the derivation cohort, comprised 1,270 triple- adjudicated 
subjects (n = 696 SLE, n = 574 controls). The criteria, with 
Criteria Definition
Class III or IV lupus nephritis on 
renal biopsy according to ISN/RPS 
2003 classification
Class III:
Focal lupus nephritis: active or inactive focal, segmental, or global endocapillary or extra-
capillary glomerulonephritis involving <50% of all glomeruli, typically with focal subendo-
thelial immune deposits, with or without mesangial alterations
Class IV:
Diffuse lupus nephritis: active or inactive diffuse, segmental, or global endocapillary or ex-
tracapillary glomerulonephritis involving ≥50% of all glomeruli, typically with diffuse sub-
endothelial immune deposits, with or without mesangial alterations. This class includes 
cases with diffuse wire loop deposits but with little or no glomerular proliferation
Positive antiphospholipid 
antibodies
Anticardiolipin antibodies (IgA, IgG, or IgM) at medium or high titer (>40 APL, GPL, or MPL, 
or >the 99th percentile) or positive anti- β2GPI antibodies (IgA, IgG, or IgM) or positive 
lupus anticoagulant
Low C3 OR low C4 C3 OR C4 below the lower limit of normal
Low C3 AND low C4 Both C3 AND C4 below their lower limits of normal
Anti- dsDNA antibodies OR anti- Sm 
antibodies
Anti- dsDNA antibodies in an immunoassay with demonstrated ≥90% specificity for SLE 
against relevant disease controls OR anti- Sm antibodies
* SLE = systemic lupus erythematosus; LDH = lactate dehydrogenase; CT = computed tomography; MRI = magnetic resonance imaging; 
EKG = electrocardiography; ISN = International Society of Nephrology; RPS = Renal Pathology Society; anti- β2GPI = anti–β2- glycoprotein I; 
 anti- dsDNA = anti–double- stranded DNA. 
† This may include physical examination or review of a photograph. 
Table 1. (Cont’d)
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positive ANA as an entry criterion, weighted criteria in 7 clini-
cal  domains (constitutional, hematologic, neuropsychiatric, mu-
cocutaneous, serosal, musculoskeletal, renal) and 3 immunologic 
domains  (antiphospholipid antibodies, low complements,  anti- Sm 
and anti- dsDNA as SLE- specific antibodies), and a classifica-
tion threshold score of ≥10 (out of a theoretical maximum of 51) 
(Figure 2), had a sensitivity of 96.1% and a specificity of 93.4% 
(Table 4). It demonstrated improved performance compared with 
the ACR 1997 and SLICC 2012 criteria.
DISCUSSION
New SLE classification criteria were developed with sup-
port by both the ACR and EULAR. Through a four- phase, 
iterative process, we have defined an additive, weighted mul-
ticriteria system that produces a measure of the relative prob-
ability that an individual can be classified as SLE. The system 
defines a threshold above which experts would classify cases 
as SLE for the purpose of research studies. We have care-
fully defined the criteria to improve reliability and precision, 
and have grouped the criteria into 10 hierarchical domains. 
We have validated the criteria against a large number of cases, 
including many patients with manifestations that resemble SLE 
but who do not have SLE. This approach, as well as the result-
ing criteria system, represents a paradigm shift for the classi-
fication of SLE.
We have defined positive ANA at any time as required 
entry criterion. There were three possible ways to deal with 
ANA testing. The previous criteria sets have treated ANA the 
same as the much more specific antibodies against Sm and 
dsDNA, which we considered suboptimal given important dif-
ferences in sensitivity and specificity. We could have excluded 
ANA completely in classifying lupus, but we still consider ANA 
a useful test and concept. We therefore decided to test ANA 
as an entry criterion, which reflects the use of ANA as a highly 
sensitive screening test.
Criteria using ANA as entry criterion had better performance. 
During the phase I Delphi exercise, 58% of SLE experts did not 
feel comfortable and an additional 19% were uncertain about 
classifying a patient with SLE in the absence of ever having a 
Table 2. Relative weights of the additive classification criteria items*
Domain Item Original Modification Revised Simplified
Constitutional Fever 13 13 2
Hematologic Leukopenia 12 +7 19 3




Neuropsychiatric Delirium 12 12 2
Psychosis 20 20 3
Seizure 34 34 5
Mucocutaneous Alopecia 13 13 2
Oral ulcers 14 14 2
SCLE/DLE 29 29 4
ACLE 38 38 6
Serosal Effusion 34 34 5
Acute pericarditis 38 38 6
Musculoskeletal Joint involvement 34 +4 38 6
Renal Proteinuria 27 27 4
Class II/V 55 55 8
Class III/IV 74 74 10
Antiphospholipid 
antibodies
Antiphospholipid 13 13 2
Complements C3 or C4 low 19 19 3
C3 and C4 low 27 27 4
SLE- specific antibodies Anti- Sm 40 40 6
Anti- dsDNA 38 38 6
* Weights derived from the phase III consensus meeting with multicriteria decisions analysis (original), added points for 
 leukopenia and joint involvement (modification), the resulting weights (revised), and the final simplified weights (simplified). 
SCLE = subacute cutaneous lupus erythematosus; DLE = discoid lupus erythematosus; ACLE = acute cutaneous lupus erythema-
tosus; SLE = systemic lupus erythematosus; anti- dsDNA = anti–double- stranded DNA. 
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positive ANA (17). The systematic literature review and meta- 
regression of data on 13,080 subjects demonstrated ANA ≥1:80 
to have a sensitivity of 98% with a lower limit of the 95% CI at 
97% (16). In the phase I early SLE cohort, 99.5% of the 389 SLE 
patients were ANA positive (18). The frequencies of ANA- positive 
SLE patients in the derivation and validation cohorts (99.6% and 
99.3%, respectively) were in the same range. Since both in the 
early SLE cohort and in the derivation and validation cohorts, 
patients were included in many centers worldwide independent of 
ANA positivity, the latter data provide additional support for ANA 
as an entry criterion.
Using ANA as entry criterion means the new criteria cannot 
classify SLE among patients who are persistently ANA negative. 
While possibly also distinguished by lower cytokine levels (27) 
and lower efficacy of immunomodulatory treatment (28), such a 
subgroup of patients exists. Although small, it may vary in size 
Table 3. Demographic characteristics of the derivation and validation cohorts*
Derivation cohort Validation cohort
SLE Non- SLE SLE Non- SLE
n 501 500 696 574
Female/male 447/54 421/79 608/88 490/84
Age, mean ± SD years 45 ± 14 54 ± 16 45 ± 14 56 ± 16
Disease duration, mean ± SD years 11 ± 8 9 ± 8 11 ± 8 9 ± 8
Ethnicity
Black 29 10 56 12
East Asian 36 29 53 34
Hispanic 59 48 73 51
South/Southeast Asian 16 6 21 11
White 355 404 480 461
Other 6 3 13 5
SLE 501 696
Non- SLE 500 574
Adult- onset Still’s disease 2 11
Autoimmune thyroiditis 6 5
Behçet’s disease 7 9
Cancer 2 3
Inflammatory myositis 37 27
Fibromyalgia 6 3
Membranous nephritis 11 14
Mixed connective tissue disease 9 15
Osteoarthritis 2 0
Primary antiphospholipid antibody 
syndrome
45 48
Psoriatic arthritis 12 9
Rheumatoid arthritis 94 110
Sarcoidosis 2 2
Sjögren’s syndrome 112 124
Spondyloarthritis 5 5
Systemic sclerosis 99 120
Tuberculosis 0 2




Viral infection 5 5
Other 19 29
* Inflammatory myositis includes dermatomyositis, polymyositis, and juvenile dermatomyositis. SLE = systemic lupus 
erythematosus. 
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in different populations (16). This patient subset needs to be put 
high on the scientific agenda for further investigation. Additional 
characterization of this phenomenon may lead to an alternative 
entry criterion for this small group of patients. For the moment, we 
still think it is acceptable to exclude ANA- negative patients from 
clinical trials.
Molecular classification criteria were also considered during 
the development of these criteria (29). Many novel biomarkers were 
Figure 2. Classification criteria for systemic lupus erythematosus (SLE). § = additional criteria within the same domain will not be counted; * = 
in an assay with 90% specificity against relevant disease controls. Anti- β2GPI = anti–β2- glycoprotein I; anti- dsDNA = anti–double- stranded DNA.
Entry criterion
Antinuclear antibodies (ANA) at a titer of ≥1:80 on HEp-2 cells or an equivalent positive test (ever)
If absent, do not classify as SLE
If present, apply additive criteria
Additive criteria
Do not count a criterion if there is a more likely explanation than SLE.
Occurrence of a criterion on at least one occasion is sufficient.
SLE classification requires at least one clinical criterion and ≥10 points.
Criteria need not occur simultaneously.
Within each domain, only the highest weighted criterion is counted toward the total score§.
Clinical domains and criteria Weight Immunology domains and criteria Weight
Constitutional Antiphospholipid antibodies
Fever 2 Anti-cardiolipin antibodies OR
Hematologic Anti-β2GP1 antibodies OR
Leukopenia 3 Lupus anticoagulant 2
Thrombocytopenia 4 Complement proteins
Autoimmune hemolysis 4 Low C3 OR low C4 3
Neuropsychiatric Low C3 AND low C4 4
Delirium 2 SLE-specific antibodies 
Psychosis 3 Anti-dsDNA antibody* OR




Subacute cutaneous OR discoid lupus  4
Acute cutaneous lupus 6
Serosal






Renal biopsy Class II or V lupus nephritis 8
Renal biopsy Class III or IV lupus nephritis 10
Total score:
Classify as Systemic Lupus Erythematosus with a score of 10 or more if entry criterion fulfilled.
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nominated, such as increased circulating B lymphocyte stimulator 
(BLyS), interferon- γ (IFNγ)–induced protein 10 kd  (IP- 10), mono-
cyte chemoattractant protein 1 (MCP- 1), tumor necrosis factor α 
(TNFα), type I IFN signature, or increased Th17 and plasma cell 
populations. They were all voted out in the expert Delphi exercise, 
largely because of limited availability in the clinical setting and/or 
insufficient evidence (5). However, inclusion of novel biomarkers, 
beyond autoantibodies, may ultimately further improve the speci-
ficity of SLE classification, increase alignment of classification with 
underlying disease pathogenesis, and improve the performance 
and information content of clinical trials. Thus, testing of biomark-
ers against these criteria is an important area for future research.
A new clinical criterion, unexplained fever, turned out to 
be common and remarkably characteristic for SLE. However, 
since infections are a major cause of death in SLE, it is of utmost 
importance to stress that fever, like all other criteria manifesta-
tions, should only be counted if no better explanation exists, 
and that infections have to be suspected first in any patient with 
(potential) SLE, particularly when C- reactive protein is elevated 
(30). The concept that all criteria are only to be counted if SLE is 
thought to be the most likely cause of the manifestation (i.e., no 
other more likely cause exists) is central to these new EULAR/
ACR criteria, and is explicitly stated as an overarching principle. 
Some criteria, such as delirium, psychosis, and acute pericardi-
tis, were in part redefined based on existing scientific definitions 
(22). Where alternative definitions were used, the performance 
of the alternative definitions was comparatively evaluated in the 
derivation cohort.
The differential weighting of criteria better represents their rel-
ative contribution to an individual’s classification of SLE. For SLE, 
renal biopsy with class III or IV lupus nephritis carries the most 
weight and in the presence of a positive ANA is enough to classify 
a patient as SLE. This further develops a concept of the SLICC 
criteria (9) and reflects the current thinking of SLE experts; in the 
Delphi exercise, 85% would classify SLE on renal pathology alone 
(17). Renal biopsy with class II or V lupus nephritis still carries a 
large weight (8 points) but is not by itself sufficient for the classifi-
cation of SLE.
The numerical goal of this project was to keep the specificity 
similar to the specificity of the ACR 1997 criteria, but increase 
the sensitivity to the high sensitivity level of the SLICC criteria, if 
possible. The validation cohort data suggest that this goal has 
been achieved. From our data, it appears that the SLICC cri-
teria increase in sensitivity was to a significant degree founded in 
accepting renal histology and adding subacute cutaneous lupus 
and low complement levels. These three advances are mirrored 
in the current criteria. Many of the other additional symptoms of 
the SLICC criteria were of very low frequency. Specificity was 
increased by weighting of criteria, by the NGT expert panel deci-
sion to not allow lymphopenia to go forward, and, importantly, by 
the decision that no criterion be counted if better explained by 
another condition.
The new criteria provide a simple, directed, and highly accu-
rate method for classifying SLE. An electronic “app” is in prepa-
ration, which will assist in the use of these criteria. However, it 
is important to stress that classification criteria are not designed 
for diagnosis or treatment decisions (5). They should never be 
used to exclude patients who do not fully meet these criteria 
from receiving appropriate therapies. This is also pertinent to 
patients with ANA- negative SLE discussed above. Diagnosis of 
SLE remains the purview of an appropriately trained physician 
evaluating an individual patient (5).
The new SLE classification system also provides new 
research opportunities. With much interest in early or latent 
SLE (31,32), the additive point system and the relative prob-
ability of classification it produces allows for systematic study 
of individuals who fall below the classification threshold. This 
will facilitate studies of disease evolution and early interven-
tion. Furthermore, the use of an additive scoring system will 
allow for studying the idea of “ominousity,” that is, the potential 
implications of having very high scores on disease severity and 
subsequent prognosis. This work would need to reconsider the 
Table  4. Operating characteristics of the new classification criteria compared with the ACR 1997 and SLICC 2012 








Sensitivity (95% CI) 0.85 (0.81–0.88) 0.97 (0.95–0.98) 0.98 (0.97–0.99)
Specificity (95% CI) 0.95 (0.93–0.97) 0.90 (0.87–0.92) 0.96 (0.95–0.98)
Combined (95% CI) 1.80 (1.76–1.83) 1.87 (1.84–1.90) 1.94 (1.92–1.96)
Validation
Sensitivity (95% CI) 0.83 (0.80–0.85) 0.97 (0.95–0.98) 0.96 (0.95–0.98)
Specificity (95% CI) 0.93 (0.91–0.95) 0.84 (0.80–0.87) 0.93 (0.91–0.95)
Combined (95% CI) 1.76 (1.73–1.80) 1.80 (1.77–1.84) 1.90 (1.87–1.92)
* ACR = American College of Rheumatology; SLICC = Systemic Lupus International Collaborating Clinics; EULAR = Euro-
pean League Against Rheumatism; 95% CI = 95% confidence interval. 
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relative contribution of individual criteria (weights) and consider 
additional criteria that potentially contribute to ominousity.
It is anticipated that other groups will test these criteria, which 
will constitute important external validation. This will be particu-
larly important for pediatric SLE and those with organ- dominant, 
for example, skin- dominant, disease, since it is a limitation of this 
criteria project that the patient cohorts do not represent these 
subgroups. Similar limitations also pertain to several racial/ethnic 
groups (for example, African American/Black, Hispanic, and Asian 
patients) and to men with SLE, each only included in lower numbers 
(Table 3). It is important to independently test the EULAR/ACR cri-
teria in these subgroups. Leukocyte counts, for example, are more 
frequently below 4,000/mm3 in African Americans (33), which may 
have an influence on criteria performance. It is also possible that the 
academic center patient populations included differ from patients in 
community practice clinics. Investigators testing the new criteria in 
different populations are reminded about the critical importance of 
the correct attribution of each criterion. Criteria can only be counted 
when not better explained by another condition (see Supplemen-
tary Table 2, on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40930/abstract). The attri-
bution process requires diligence and clinical experience.
In summary, our multiphase methodologic approach and 
ensuing classification system using ANA as an entry criterion 
and weighted, hierarchically clustered criteria constitute a par-
adigm shift in the classification of SLE. These criteria have 
excellent performance characteristics and face validity, as the 
structure and weighting were designed to reflect current thinking 
about SLE. The inclusion of fever assists with the classification 
of early SLE. The separation of renal biopsy findings reflects their 
differential impact on the probability of SLE classification. These 
criteria have strong operating characteristics, with excellent sen-
sitivity and specificity. This classification system was built using 
rigorous methodology that was both data- driven and expert- 
based. With the inclusion of over 200 SLE experts from multi-
ple countries and medical disciplines, methodologists, patient 
advocates, and over 4,000 subjects, this work is the largest 
international, collaborative SLE classification effort to date.
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